running continuously for long periods without trouble or attention.
These requirements have been met by two devices. The first is based on the peristaltic pump designed as a proportioning pipette by Dr I D P Wootton of the Postgraduate Medical School. This pump, when driven at one revolution per minute by an induction motor, is quiet, extremely simple and very reliable. The tubing used in the pump head is sterilized by autoclaving. A pressure switch of the conventional diaphragm type is included in the inflow line; the detachable plate can be sterilized by autoclaving and the diaphragm by treatment with 0 5 %Y alcoholic Bradosol. This is a constant volume device with an output of 400 ml daily almost completely independent of inflow resistance. The pressure switch is set to operate at a pressure 100 mm Hg above the patient's measured arterial pressure.
The second pump we have used successfully is the Distillers Company's Micropump, which was described in an earlier form by Anderson et al. (1961) . This is a diaphragm pump, the head of which is removable for autoclaving. The diaphragm is operated by a hydraulic system driven from an exceptionally quiet, low-voltage induction motor. It is possible to.-vary the infusion rate between 0 and 100 ml per hour, and again the output is largely independent of resistance. The same pressure switch is used.
In comparison with the peristaltic pump, the diaphragm pump is much more trouble to set up, clean and sterilize, but it is considerably quieter and is capable of providing a variety of infusion rates. Both pumps have been subjected to extensive laboratory trials against simulated arterial pressures as high as 350 mm Hg and have been entirely satisfactory. Clinical trials are not yet sufficiently extensive for us to have developed a preference for either pump, but results are sufficiently encouraging to suggest that they may eventually replace the drip technique even for normotensive patients. Acknowledgments: We should like to thank the staff of the Engineering Department of the Distillers Company Ltd, Development Division, for their assistance, and Dr C N Brown, also of the Distillers Company, for providing the D.C.L. Micropumps. Mr A P Evans, of Delta Technical Services, developed the pressure switches. Financial support for this work was provided by Mr Geoffrey Harmsworth, the British Empire Cancer Campaign and the Board of Governors of Westminster Hospital.
One of us (D E P) is in receipt of a full time grant from the British Empire Cancer Campaign. Whatever the future may hold in the way of treatment for malignant tumoursbe it surgery or hormones, cytotoxic agents or irradiation, singly or in combinationthere is no doubt that perfusion techniques continue to advance with an acceleration which justifies constant revision of our therapeutic methods in an attempt to improve the control of the disease. My remarks are based upon a series of 85 cases seen at Westminster. We have demonstrated that extracorporeal perfusion or continuous intraarterial infusion of antimetabolites such as methotrexate can produce regressionsometimes miraculous regression of advanced epithelial tumours, melanomata and even mesodermal growths. Moreover regression has been achieved in lesions recurrent after or primarily resistant to irradiation.
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Why, then, do we not advocate that these methods be applied wholesale and immediately to all cases, abandoning major surgical operations and expensive and complicated irradiation machinery? The regression achieved in most cases has been incomplete and in a high proportion it is not lasting, Mr G Westbury has drawn attention to an observation that the effectiveness of intra-arterial therapy might be impaired by vascular changes in an already heavily irradiated area, and indeed better results have lately been obtained in some unirradiated cases.
Nevertheless, at Westminster we are of the opinion that the results do not justify the wholesale use of intravascular chemotherapy in previously untreated cases especially where facilities exist for adequately proved conventional methods. I can hardly emphasize this point too strongly. Whenever the disease is accessible, for example, in the lip, tongue or the buccal mucosa, the best treatment, to bepreferred above all others, is interstitial irradiation with the hard gamma rays from radium needlesit is a method which gives results that have never been surpassed, and where applicable it remains the treatment of choice today. For epitheliomas of the floor of the mouth, the tonsil and pharynx, no method of treatment yet devised has surpassed supervoltage irradiation from telecobalt units, with or without rotating beams or the megavoltage beam from a linear accelerator. Perfusion should, for the present, be reserved for those cases where surgery and irra-diation have failed to control the disease. Block dissection remains the treatment of choice for operable malignant glands in the neck where they are the site of metastases from epithelial tumours.
A further major disadvantage of intra-arterial perfusion in the control of disease in the cervical glands is the strict limitation of this effect to the vascular bed. The mortality and morbidity associated with prolonged intra-arterial infusion greatly exceeds that of irradiation.
Notwithstanding these disadvantages, if the method is restricted to those cases of epithelial cancer where irradiation has failed and surgery is no longer feasible, remarkable palliation with relief of pain and shrinkage of the growth can be achieved.
The indication par excellence for perfusion is in malignant melanomata -not the early single tumour where wide excision with block dissection of the regional nodes remains the treatment to be recommended, but in the advanced case where no method has yet been devised to control this terrible disease which can compare with the success achieved by intra-arterial extracorporeal perfusion.
To summarize, then, the position is as follows: There are two clear-cut and incontrovertible indications for the use of intra-arterial methods of chemotherapy: (1) Uncontrolled malignant melanoma confined to a limbhere extracorporeal perfusion is to be preferred to the unsatisfactory alternative, ablation. (2) Head and neck cancer recurrent or primarily resistant to irradiation and unsuitable for surgery.
In these patients we can offer hope of relief of pain, shrinkage of the tumour and even, on occasion, prolonged control of the disease.
In addition to these two groups of cases we have treated a number of patients with advanced epithelial cancer of the pelvis, following failure of irradiation or surgery for carcinoma of the cervix, by simple intra-aortic injections of alkylating agents. Results were encouraging, and lately we have had some success in the control of advanced brain tumours by the same technique.
We have tried to show how these new techniques have been integrated into the management of malignant disease in a large, well-equipped radiotherapy centre. The position, however, is changing rapidly and on the basis of two years' work and the treatment of some 85 cases, we feel that it is now reasonable to investigate the use of some of these methods in combination with older conventional techniques as part of the primary attack on certain carefully selected groups of cancer, especially those with a poor prognosis. Two examples are advanced disease of the antrum where glandular spread is late and where intraarterial infusion in combination with irradiation may improve the outlook in this disappointing group; and primary, early melanoma where we think that there is also a case for adding extracorporeal perfusion to the standard attack.
Finally, I wish to thank our resident and nursing staff for their enthusiasm and support in this long, hard and exacting work. I wish to thank also my colleagues at Westminster and at other Hospitals for cases referred to us.
